TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank67
3Y CAGR+8.3%
5Y CAGR+34.4%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
+8.3%/yr
Annual compound
5Y CAGR
+34.4%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
4.4x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$152.41M-14.7%
2024$178.69M+34.0%
2023$133.36M+11.1%
2022$120.03M-25.6%
2021$161.41M+363.9%
2020$34.79M-16.7%
2019$41.76M-